Abcellera and everest medicines announce multi-target collaboration to advance new antibody therapies

Vancouver, british columbia and shanghai, sept. 22, 2021 /prnewswire/ -- abcellera (nasdaq: abcl) and everest medicines limited (hkex 1952.hk, "everest") announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by everest.
ABCL Ratings Summary
ABCL Quant Ranking